SYNTHETIC LETHALITY OF CDK INHIBITION AND DOXORUBICIN IN TRIPLE-NEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION
Dissertations and Theses (Open Access)
Part of the Medicine and Health Sciences Commons
Part of the Medicine and Health Sciences Commons